Literature DB >> 29294383

A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury.

David J Titus1, Nicole M Wilson1, Oscar Alcazar1, Dale A Calixte1, W Dalton Dietrich1, Mark E Gurney2, Coleen M Atkins3.   

Abstract

Traumatic brain injury (TBI) significantly decreases cyclic AMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments. Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation. Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, negative allosteric modulator, D159687. In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI. To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. After 3 months of recovery, animals were treated with D159687 (0.3 mg/kg, intraperitoneally) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task. Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals. Assessment of hippocampal slices at 3 months post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation. These results demonstrate that a negative allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Fluid Percussion Injury; Hippocampus; Memory; Phosphodiesterase; Traumatic brain injury

Mesh:

Substances:

Year:  2017        PMID: 29294383      PMCID: PMC5844849          DOI: 10.1016/j.nlm.2017.12.008

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  67 in total

Review 1.  Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention.

Authors:  Alok Kumar; David J Loane
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

2.  Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease.

Authors:  Albert Giralt; Ana Saavedra; Olga Carretón; Xavier Xifró; Jordi Alberch; Esther Pérez-Navarro
Journal:  Hum Mol Genet       Date:  2011-08-11       Impact factor: 6.150

3.  Phosphodiesterase isoform-specific expression induced by traumatic brain injury.

Authors:  Anthony A Oliva; Yuan Kang; Concepcion Furones; Ofelia F Alonso; Olga Bruno; W Dalton Dietrich; Coleen M Atkins
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

4.  Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect.

Authors:  J A Cherry; R L Davis
Journal:  J Comp Neurol       Date:  1999-05-03       Impact factor: 3.215

5.  Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability.

Authors:  Sarah N Rampersad; Jeffrey D Ovens; Elaine Huston; M Bibiana Umana; Lindsay S Wilson; Stuart J Netherton; Martin J Lynch; George S Baillie; Miles D Houslay; Donald H Maurice
Journal:  J Biol Chem       Date:  2010-08-23       Impact factor: 5.157

6.  Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.

Authors:  S-L Catherine Jin; Linda Lan; Maria Zoudilova; Marco Conti
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

Review 7.  Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.

Authors:  Han-Ting Zhang
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice.

Authors:  Cong Zhang; Yufang Cheng; Haitao Wang; Chuang Wang; Steven P Wilson; Jiangping Xu; Han-Ting Zhang
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus.

Authors:  Nicole M Wilson; David J Titus; Anthony A Oliva; Concepcion Furones; Coleen M Atkins
Journal:  Front Syst Neurosci       Date:  2016-02-05

10.  Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System.

Authors:  Chong Zhang; Ying Xu; Han-Ting Zhang; Mark E Gurney; James M O'Donnell
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

View more
  7 in total

Review 1.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

2.  Sex differences in cued fear responses and parvalbumin cell density in the hippocampus following repetitive concussive brain injuries in C57BL/6J mice.

Authors:  Laura B Tucker; Brian S Winston; Jiong Liu; Alexander G Velosky; Amanda H Fu; Antigone A Grillakis; Joseph T McCabe
Journal:  PLoS One       Date:  2019-09-05       Impact factor: 3.240

3.  A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury.

Authors:  Rudy Schreiber; Romain Hollands; Arjan Blokland
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior.

Authors:  Graeme B Bolger; Lisa High Mitchell Smoot; Thomas van Groen
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

Review 5.  Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Heng Li; Jianping Zuo; Wei Tang
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810

6.  Positive allosteric modulation of the α7 nicotinic acetylcholine receptor as a treatment for cognitive deficits after traumatic brain injury.

Authors:  David J Titus; Timothy Johnstone; Nathan H Johnson; Sidney H London; Meghana Chapalamadugu; Derk Hogenkamp; Kelvin W Gee; Coleen M Atkins
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

Review 7.  Novel Synthetic and Natural Therapies for Traumatic Brain Injury.

Authors:  Denise Battaglini; Dorota Siwicka-Gieroba; Patricia Rm Rocco; Fernanda Ferreira Cruz; Pedro Leme Silva; Wojciech Dabrowski; Iole Brunetti; Nicolò Patroniti; Paolo Pelosi; Chiara Robba
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.